First trimester pregnancy-associated plasma protein-A and birth weight.

[1]  C. Randazzo,et al.  Correlation of neonatal weight with maternal serum levels of pregnancy-associated plasma protein-A during the first trimester of pregnancy: a retrospective study , 2015, Journal of perinatal medicine.

[2]  G. Shaw,et al.  Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin , 2014, American Journal of Perinatology.

[3]  D. Krantz,et al.  Elevated first trimester PAPP‐A is associated with increased risk of placenta accreta , 2014, Prenatal diagnosis.

[4]  A. Khalil,et al.  Association between first‐trimester maternal serum pregnancy‐associated plasma protein‐A and obstetric complications , 2013, Prenatal diagnosis.

[5]  G. Shaw,et al.  Association of early-preterm birth with abnormal levels of routinely collected first- and second-trimester biomarkers. , 2013, American journal of obstetrics and gynecology.

[6]  F. Audibert,et al.  First-Trimester Prediction of Birth Weight , 2013, American Journal of Perinatology.

[7]  F. Lorey,et al.  Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow‐up services , 2012, Prenatal diagnosis.

[8]  M. Rodger,et al.  Significance of IGFBP-4 in the development of fetal growth restriction. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  F. Mcauliffe,et al.  Prediction and prevention of the macrosomic fetus. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[10]  M. Ryynänen,et al.  The secretion of PAPP-A, ADAM12, and PP13 correlates with the size of the placenta for the first month of pregnancy. , 2011, Placenta.

[11]  F. Lorey,et al.  Detection rate of quadruple‐marker screening determined by clinical follow‐up and registry data in the statewide California program, July 2007 to February 2009 , 2011, Prenatal diagnosis.

[12]  Kypros H. Nicolaides,et al.  Placental Volume at 11–13 Weeks’ Gestation in the Prediction of Birth Weight Percentile , 2011, Fetal Diagnosis and Therapy.

[13]  N. Uldbjerg,et al.  Biology of pregnancy‐associated plasma protein‐A in relation to prenatal diagnostics: an overview , 2010, Acta obstetricia et gynecologica Scandinavica.

[14]  H. D. de Bie,et al.  Brain Development, Intelligence and Cognitive Outcome in Children Born Small for Gestational Age , 2010, Hormone Research in Paediatrics.

[15]  D. Arduini,et al.  First‐Trimester Placental Volume and Vascularization Measured by 3‐Dimensional Power Doppler Sonography in Pregnancies With Low Serum Pregnancy‐Associated Plasma Protein A Levels , 2009, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[16]  F. Lorey,et al.  Triple-Marker Prenatal Screening Program for Chromosomal Defects. , 2009, Obstetrics and gynecology.

[17]  L. Jelliffe‐Pawlowski,et al.  Triple-Marker Prenatal Screening Program for Chromosomal Defects , 2009, Obstetrics and gynecology.

[18]  V. Désilets,et al.  Obstetrical complications associated with abnormal maternal serum markers analytes. , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[19]  E. M. Lundgren,et al.  Effects of being born small for gestational age on long-term intellectual performance. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[20]  S. Peterson,et al.  First-trimester pregnancy-associated plasma protein A and subsequent abnormalities of fetal growth. , 2007, American journal of obstetrics and gynecology.

[21]  M. Alberry,et al.  Management of fetal growth restriction , 2006, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[22]  Eugenia K. Pallotto,et al.  Perinatal Outcome and Later Implications of Intrauterine Growth Restriction , 2006, Clinical obstetrics and gynecology.

[23]  C. Sheridan.  Intrauterine growth restriction--diagnosis and management. , 2005, Australian family physician.

[24]  F. Malone,et al.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). , 2004, American journal of obstetrics and gynecology.

[25]  L. Giudice,et al.  Identification and Regulation of the IGFBP-4 Protease and Its Physiological Inhibitor in Human Trophoblasts and Endometrial Stroma : Evidence for Paracrine Regulation of IGF-II Bioavailability in the Placental Bed during Human Implantation , 2002 .

[26]  L. Giudice,et al.  Role of the IGF system in trophoblast invasion and pre-eclampsia. , 1999, Human reproduction.

[27]  J R Yates,et al.  The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Vinatier,et al.  Fetal macrosomia: risk factors and outcome. A study of the outcome concerning 100 cases >4500 g. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[29]  J. Himes,et al.  A United States National Reference for Fetal Growth , 1996, Obstetrics and gynecology.

[30]  F. Prefumo,et al.  Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. , 2008, Fertility and sterility.